Biogen has added a preclinical-stage drug candidate for Parkinson's disease via a $722.5 million licensing agreement with Alectos Therapeutic, as it continues to rebuild a pipeline behind its side ...

With the prospects for its Alzheimer’s drug aducanumab still up in the air, Biogen has moved to shore up its late-stage pipeline with a $3 billion licensing deal with Sage that adds drugs for ...

Q1 2025 Management View CEO Chris Viehbacher highlighted Biogen's evolving portfolio, with newer products such as LEQEMBI, SKYCLARYS, and ZURZUVAE now comprising 45% of product revenue. He emphasized ...

Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity ...

Biogen is embarking on a new chapter in the very heart of the community that has shaped our success. “Our new space will support the advancement of our pipeline of breakthrough medicines by bringing ...

He said the company would "invest significantly" in product launches while continuing to build out its early stage pipeline. Biogen's most anticipated new product may be BG-12, an MS treatment ...